Table 3.

UKU side-effects arranged by significance. Beta, standard error and p-values were calculated using GEE models adjusting for baseline UKU scores and represent the difference in reported SSRI side-effects between escitalopram-treated and placebo participants.

UKU Item	Side-effect	β (SE) for escitalopram>placebo difference	p
Q7	Increased duration sleep	1.13 (.36)	0.002
Q22	Dry mouth	.55 (.23)	0.02
Q42	Diminished sexual desire	1.10 (.47)	0.02
Q24	Diarrhea	.46 (.23)	0.04
Q32	Pruritus	1.30 (.22)	0.05
Q26	Micturition disturbance	.75 (40)	0.06
Q30	Increased tendency to sweat	.44 (27)	0.10
Q15	Tremor	.52 (.36)	0.15
Q2	Asthenia/Lassitude/Fatigue	.27 (.20)	0.17
Q11	Dystonia	.72 (.55)	0.19
Q33	Photosensitivity	.72 (.56)	0.20
Q27	Polyuria/Polydipsia	.31 (.25)	0.21
Q9	Increased dreaming	.18 (.25)	0.47
Q31	Rash	.28 (.39)	0.48
Q34	Increased pigmentation	.29 (.49)	0.56
Q19	Headache	.08 (.19)	0.67
Q1	Concentration difficulties	.08 (.21)	0.71

Proc Genmod in SAS was used to calculate GEE models, with a Z test used to test for the significance of the GEE parameter.